Qualcomm Makes Medical Tech Deals With AlertWatch, PeriGen

Qualcomm Logo AH 1

Qualcomm inked two license agreements with American patient monitoring companies PeriGen and AlertWatch, the chipmaker announced Wednesday. Under the terms of the new deals, Qualcomm will be leveraging the firms’ solutions to improve its own offerings, in addition to selling them to its existing and future clients. In AlertWatch’s case, the company obtained exclusive rights to retail FDA-approved AlertWatch:OR service for secondary patient monitoring specifically designed for operating rooms. PeriGen’s software has also been greenlit by the FDA but focuses on providing perinatal monitoring meant to assist labor and delivery clinicians in taking care of their pregnant patients. It does so by providing them with vast amounts of highly organized data that’s analyzed with the help of the firm’s proprietary algorithms.

PeriGen’s product portfolio is meant to be highly universal in nature and supports a wide variety of Internet-enabled devices that help it collect data in hospitals for later use. The ultimate goal of the platform is to improve the overall efficiency of perinatal care through robust insights that help clinicians make maximally informed decisions in regards to caring for their patients. Qualcomm will be selling and licensing the PeriWatch Vigilance warning system meant to assist obstetricians by notifying them of patients whose conditions are worsening in real time. The solution monitors everything from fetal heart rate and contractions to general maternal vital signs and is compatible with offerings from Qualcomm Life’s Capsule series of intelligent patient care solutions.

The same product portfolio also offers native support for AlertWatch:OR that’s primarily designed to assist anesthesiologists in making informed decisions during surgery. AlertWatch’s software tracks vital signs, drug and fluid levels, blood loss, and other metrics clinicians are interested in. The app can also analyze medical histories and take pre-existing conditions into account while doing calculations. Both of the new licensing agreements should strengthen Qualcomm’s position in the medical technology segment moving forward and are understood to be long-term in nature. Qualcomm has been showcasing its latest telecommunications solutions at the ongoing Mobile World Congress over the course of this week and is expected to play a major role in the deployment of 5G networks in the United States. The company is presently also fighting back against a hostile takeover attempt organized by Broadcom.